iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution
UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a...
Company
BMS Announces Positive Outcomes for BMS-986278 in Progressive Pulmonary Fibrosis Study
Bristol-Myers Squibb (BMS; NYSE: BMY) has released the final results from a Phase II trial...
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as...
EMA Reviews Janssen’s Balversa for Advanced Urothelial Carcinoma with FGFR3 Alterations
The European Medicines Agency (EMA) has accepted for review a filing made by the Janssen...
United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced tacit clinical trial approval...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase Ib/III Study of Dalpiciclib in mHSPC
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...
Otsuka and Shape Therapeutics Partner on Ophthalmology Gene Therapies Development
Japan drug maker Otsuka (OTCMKTS: OTSKY) and US firm Shape Therapeutics have announced a strategic...
Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial
Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...
Pfizer and Valneva’s Lyme Disease Vaccine VLA15 Shows Promise as Booster in Pediatric Trials
Partners Pfizer (NYSE: PFE) and Valneva SE (NASDAQ: VALN) have revealed that their Lyme disease...
European Commission Approves Pediatric Indication for MSD’s Ervebo Ebola Vaccine
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) approval for...
Cutia Therapeutics’ CU-40102 Meets Primary Endpoint in Phase III Study for Androgenic Alopecia
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its Phase III clinical study...
AstraZeneca’s Ultomiris Faces FDA Rejection for NMOSD Indication Extension
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has received a rejection from the US Food...
Chengdu Kanghua Receives FDA Approval for Clinical Trial of Norovirus Vaccine
China-based Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has announced that it has received...
Merck’s Keytruda Approved in China for MSI-H/dMMR Advanced Solid Tumors: A Biomarker-Driven Milestone
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its programmed...
Biocytogen Pharmaceuticals Enters Agreement with Myricx Bio for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody evaluation, option, and...
Danaher Partners with Beijing’s Changping District to Accelerate Science and Technology Innovation Center
US-headquartered Danaher (NYSE: DHR), a Fortune 500 science and technology innovator, has entered into a...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Pancreatic Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Shanghai Haihe Pharmaceutical’s Glumetinib Filed for Marketing in Japan for NSCLC Treatment
Shanghai Haihe Pharmaceutical Co., Ltd has announced the filing for marketing approval in Japan for...
Eminence Biotechnology Launches Fully Operational Cell Culture Media Facility in Suzhou
China-based Eminence Biotechnology (Suzhou) Co., Ltd. has announced the full operation of its state-of-the-art cell...
LIQUIK Study Interim Results to Showcase Lucence’s Liquid Biopsy Advancements at WCLC 2023
Precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto, California,...